Vir Biotechnology receives $50M from BARDA for next-gen COVID-19 mAb and pandemic preparedness

Vir Biotechnology, Inc.

BARDA awards $40M via Project NextGen for VIR-7229 Phase 1 trial, expected completion H2 2025.
Additional $10M for discovery of mAbs against a second pandemic-potential pathogen.
Vir also receives ~$11M to wind down PENINSULA trial of influenza A mAb VIR-2482.
Existing BARDA Agreement allows up to $1B total investment; $55M already provided for VIR-2482.
Funds support alternative mAb delivery technologies for COVID-19 and broader pandemic response.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vir Biotechnology, Inc. amended BARDA Agreement with Biomedical Advanced Research and Development Authority (BARDA) valued at $50 million (effective 2023-09-29).

Action: amendment
Counterparty: Biomedical Advanced Research and Development Authority (BARDA)
Value: $50 million
Effective: 2023-09-29

Exact text from the filing

On September 29, 2023, Vir Biotechnology, Inc. (the “Company” or “Vir”) and the Biomedical Advanced Research and Development Authority (“BARDA”), part of the U.S. Department of Health and Human Services’ (“HHS”) Administration for Strategic Preparedness and Response, entered into Amendment No. P00001 to their Other Transaction Authority Agreement (as amended, the “BARDA Agreement”) pursuant to which BARDA awarded the Company $50 million in new funding

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-249556

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.